The endocannabinoid system in appetite regulation and treatment of obesity
Authors:
Open Access
- 18 September 2024
- journal article
- review article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (5) , e70009
Abstract
The endocannabinoid system (ECS) is a complex cell‐signaling system that is responsible for maintaining homeostasis by modulating various regulatory reactions in response to internal and environmental changes. The influence of ECS on appetite regulation has been a subject of much recent research, however, the full extent of its impact remains unknown. Current evidence links human obesity to ECS activation, increased endocannabinoid levels in both central and peripheral tissues, along with cannabinoid receptor type 1 (CBR1) up‐regulation. These findings imply the potential pharmacological use of the ECS in the treatment of obesity. Here, we present various pathophysiological processes in obesity involving the ECS, highlighting different pharmacological options for modulating endocannabinoid activity to treat obesity. However, the potential of those pharmacological possibilities remains under investigation and requires further research.Keywords
This publication has 84 references indexed in Scilit:
- The Endocannabinoid System and Eating Behaviours: a Review of the Current State of the EvidenceCurrent Nutrition Reports, 2022
- Hypothalamic endocannabinoids in obesity: an old story with new challengesCellular and Molecular Life Sciences, 2021
- Druggable Targets in Endocannabinoid Signaling2020
- Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated DiseasesCurrent Diabetes Reports, 2017
- An Introduction to the Endogenous Cannabinoid SystemBiological Psychiatry, 2016
- Cannabis sativaand the Endogenous Cannabinoid System: Therapeutic Potential for Appetite RegulationPhytotherapy Research, 2011
- Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with ageDiabetologia, 2010
- The endocannabinoid system in obesity and type 2 diabetesDiabetologia, 2008
- Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa ratsHepatology, 2007
- Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese PatientsJAMA, 2006